• Jan-Ingmar Flock


    Box 112, S-129 22 Hägersten Visiting address: Västertorpsvägen 135, S-129 44 Hägersten
    +46-8-120 10 600
    +46 733 341 411
  • Andreas Andersson


    Box 112, S-129 22 Hägersten Visiting address: Västertorpsvägen 135, S-129 44 Hägersten
    +46-8-120 10 601
    +46-73-335 99 70
  • Quotes

    We are very pleased to be able to give this message when we are in an intensive phase in the development of the commercial production process
    Andreas Andersson, CEO Intervacc AB
    An important preparatory step has now been completed for the upcoming commercial large-scale production in compliance with GMP (Good Manufacturing Practice). This, in combination with the recent pre-submission meeting with the European Medicines Agency (EMA), confirms the previously established timetable for Strangvac
    Jan-Ingmar Flock, CSO Intervacc
    We are delighted with the appointment of Andreas. He has a track record of success in developing and expanding companies with a strong technology focus. This is an exciting time for Intervacc, as it prepares for the registration and commercialization of Stangvac® as well as the continued development of the Company’s other vaccine candidates.
    Björn Sjöstrand, Chairman of the Board
    The new study, in combination with previous studies, shows that intramuscular vaccination with the Strangvac vaccine provides effective protection and also a rapid immune response (booster effect) at revaccination up to one year after basic vaccination. These are pleasing results that are of great importance in the development of guidelines and vaccination programs for how Strangvac will be used. Today there is no fully safe and satisfactory vaccine against strangles on the world market, as shown by current reported outbreaks from around the world
    Jan-Ingmar Flock, CEO
    The quality requirements and the fact that several of our projects have been rated so well by independent expert reviewers in a short while, confirms that Intervacc's project portfolio for a new generation of animal health vaccines is of great interest
    CEO Jan-Ingmar Flock
    With this agreement, we have been assured that the entire manufacturing chain is in place for commercial production of Strangvac
    Jan-Ingmar Flock, CEO
    This is an important milestone in the process to complete the registration of Strangvac® and especially considering that there is a huge need for a safe and efficacious vaccine against equine strangles as evidenced by all current reported outbreaks around the world
    Jan-Ingmar Flock, CEO of Intervacc
    This is very exciting and an additional important step in Intervacc's development to become a company with several projects with high-potential in addition to Strangvac® and INV274 against pig streptococcal infection
    Jan-Ingmar Flock, CEO
    We are very pleased about this agreement, this is a significant step forward for Intervacc, which thereby enters into a new commercial production phase after successful completion of clinical trials and safety studies of Strangvac®
    Jan-Ingmar Flock, CEO
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top